385 related articles for article (PubMed ID: 16611192)
1. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience.
Tillmann HL; Hadem J; Leifeld L; Zachou K; Canbay A; Eisenbach C; Graziadei I; Encke J; Schmidt H; Vogel W; Schneider A; Spengler U; Gerken G; Dalekos GN; Wedemeyer H; Manns MP
J Viral Hepat; 2006 Apr; 13(4):256-63. PubMed ID: 16611192
[TBL] [Abstract][Full Text] [Related]
2. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group.
Perrillo R; Rakela J; Dienstag J; Levy G; Martin P; Wright T; Caldwell S; Schiff E; Gish R; Villeneuve JP; Farr G; Anschuetz G; Crowther L; Brown N
Hepatology; 1999 May; 29(5):1581-6. PubMed ID: 10216146
[TBL] [Abstract][Full Text] [Related]
3. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients.
Lee WC; Wu MJ; Cheng CH; Chen CH; Shu KH; Lian JD
Am J Kidney Dis; 2001 Nov; 38(5):1074-81. PubMed ID: 11684562
[TBL] [Abstract][Full Text] [Related]
4. Lamivudine treatment for acute severe hepatitis B: a pilot study.
Schmilovitz-Weiss H; Ben-Ari Z; Sikuler E; Zuckerman E; Sbeit W; Ackerman Z; Safadi R; Lurie Y; Rosner G; Tur-Kaspa R; Reshef R
Liver Int; 2004 Dec; 24(6):547-51. PubMed ID: 15566503
[TBL] [Abstract][Full Text] [Related]
5. The use of lamivudine for patients with acute hepatitis B (a series of cases).
Kondili LA; Osman H; Mutimer D
J Viral Hepat; 2004 Sep; 11(5):427-31. PubMed ID: 15357647
[TBL] [Abstract][Full Text] [Related]
6. Lamivudine treatment of advanced and decompensated liver disease due to hepatitis B.
Van Thiel DH; Friedlander L; Kania RJ; Molloy PJ; Hassanein T; Wahlstrom E; Faruki H
Hepatogastroenterology; 1997; 44(15):808-12. PubMed ID: 9222695
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of hepatitis B virus infection with Lamivudine after heart transplantation.
Wang SS; Chou NK; Chi NH; Hsu RB; Huang SC; Chen YS; Yu HY; Tsao CI; Ko WJ; Lai MY; Chu SH
Transplant Proc; 2006 Sep; 38(7):2138-40. PubMed ID: 16980024
[TBL] [Abstract][Full Text] [Related]
8. [Lamivudine therapy in patients with severe acute hepatitis B].
Roznovský L; Orságová I; Kloudová A; Mrázek J
Klin Mikrobiol Infekc Lek; 2007 Apr; 13(2):59-65. PubMed ID: 17599294
[TBL] [Abstract][Full Text] [Related]
9. Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat?
Tillmann HL; Zachou K; Dalekos GN
Liver Int; 2012 Apr; 32(4):544-53. PubMed ID: 22099371
[TBL] [Abstract][Full Text] [Related]
10. Lamivudine therapy for spontaneously occurring severe acute exacerbation in chronic hepatitis B virus infection: a preliminary study.
Tsubota A; Arase Y; Saitoh S; Kobayashi M; Suzuki Y; Suzuki F; Chayama K; Murashima N; Ikeda K; Kobayashi M; Kumada H
Am J Gastroenterol; 2001 Feb; 96(2):557-62. PubMed ID: 11232706
[TBL] [Abstract][Full Text] [Related]
11. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
Huang H; Cai Q; Lin T; Lin X; Liu Y; Gao Y; Peng R
Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
[TBL] [Abstract][Full Text] [Related]
12. Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series.
Huang YW; Liu CJ; Lai MY; Lee PH; Tsai MK; Wang SS; Lai MK; Kao JH
Clin Ther; 2006 Sep; 28(9):1327-34. PubMed ID: 17062306
[TBL] [Abstract][Full Text] [Related]
13. Reactivation of hepatitis and lamivudine therapy in 11 HBsAg-positive renal allograft recipients: a single centre experience.
Murakami R; Amada N; Sato T; Orii T; Kikuchi H; Haga I; Ohashi Y; Okazaki H
Clin Transplant; 2006; 20(3):351-8. PubMed ID: 16824154
[TBL] [Abstract][Full Text] [Related]
14. Acute fulminant hepatitis B in a patient with diabetic nephropathy treated successfully with concomitant lamivudine and molecular adsorbents recirculating system.
Tsai SH; Chang HM; Hsieh CB; Chao YC; Hsieh TY
J Infect; 2006 Jul; 53(1):e19-23. PubMed ID: 16269182
[TBL] [Abstract][Full Text] [Related]
15. Cadaveric renal transplantation in hepatitis B antigen-positive recipients using hepatitis B antigen-positive donor organs with lamivudine treatment.
Kim JA; Huh W; Lee KW; Kim SJ; Kim YG; Kim DJ; Joh JW; Oh HY
Transplant Proc; 2004 Jun; 36(5):1434-7. PubMed ID: 15251352
[TBL] [Abstract][Full Text] [Related]
16. The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy.
Gwak GY; Huh W; Lee DH; Choi MS; Lee JH; Koh KC; Kim SJ; Joh JW; Oh HY
Transplant Proc; 2007 Dec; 39(10):3121-6. PubMed ID: 18089336
[TBL] [Abstract][Full Text] [Related]
17. Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial.
Wiegand J; Wedemeyer H; Franke A; Rößler S; Zeuzem S; Teuber G; Wächtler M; Römmele U; Ruf B; Spengler U; Trautwein C; Bock CT; Fiedler GM; Thiery J; Manns MP; Brosteanu O; Tillmann HL;
J Viral Hepat; 2014 Oct; 21(10):744-50. PubMed ID: 24329913
[TBL] [Abstract][Full Text] [Related]
18. [Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients].
Yang Y; Yang Y; Zhang J; Yi HM; Lu MQ; Cai CJ; Li X; Jiang N; Xu C; Li H; Wang GS; Yi SH; Zhang JF; Jiang H; Yang Q; Chen GH
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1810-2. PubMed ID: 18971179
[TBL] [Abstract][Full Text] [Related]
19. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B-associated acute liver failure: immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae.
Jochum C; Gieseler RK; Gawlista I; Fiedler A; Manka P; Saner FH; Roggendorf M; Gerken G; Canbay A
Digestion; 2009; 80(4):235-40. PubMed ID: 19828954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
